Table 2.

Relationship between SPINT1-AS1 expression and clinicopathological characteristics in colorectal cancer patients

Characteristics	n	SPINT1-AS1 expression	P-value
Age (years)			0.747a
<60	64	3.695 (2.293–4.643)
≥60	86	3.810 (2.295–5.038)
Gender			0.218a
Male	97	3.680 (2.105–4.870)
Female	53	3.890 (2.640–5.010)
Tumor location			0.959a
Rectum	90	3.780 (2.345–4.845)
Colon	60	3.695 (2.228–4.950)
Tumor differentiation			0.647b
Poor	36	3.905 (2.193–4.760)
Moderate	98	3.795 (2.273–4.990)
Well	16	3.295 (2.438–4.388)
T stage			0.430a
T1–T2	37	3.070 (2.275–5.115)
T3–T4	113	3.810 (2.295–4.820)
Regional lymph node metastasis			<0.001a
Negative	66	2.640 (1.918–3.920)
Positive	84	4.365 (3.353–5.113)
Distant metastasis			<0.001a
No	132	3.365 (2.160–4.660)
Yes	18	5.150 (4.433–5.630)
Tumor size			0.410a
<5 cm	69	3.730 (2.105–5.150)
≥5 cm	81	3.780 (2.320–4.710)

Notes: Data presented as median (25%–75% interquartile range).

^aMann–Whitney U-test,

^bKruskal–Wallis test.

Abbreviation: SPINT1-AS1, serine peptidase inhibitor, Kunitz type 1 antisense RNA1.